Controlling for mammography screening in analyses of breast cancer survival and mortality has been advocated [25, 26], as MHT users undergo mammography more frequently than non-users [56, 57] and screen-detected cancers tend to be of more favorable grade, early stage, and hormone receptor-positive [56, 58, 59]. The gene discussed is NR4A1; the disease is breast carcinoma.